AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Benefits advisors need to stay proactive and help their clients leverage formulary design, clinical oversight, and ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of branded biologics looking to maintain blockbuster revenue.

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

CVS Caremark, Express Scripts and Optum Rx — the three largest pharmacy benefit managers in the U.S. — each excluded more ...

Doug Long, BA, MBA, vice president of Industry Relations at IQVIA, shares what's happening in the growing GLP-1 and biosimilars space. Long was a presenter at the annual AMCP 2025 meeting in Houston, ...

Number 5: Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in ...

However, the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on cancer drug, Imbruvica, and a slow market growth trend for Juvederm ...